94 related articles for article (PubMed ID: 12091065)
21. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Quintas-Cardama A; Kantarjian H; O'Brien S; Jabbour E; Giles F; Ravandi F; Faderl S; Pierce S; Shan J; Verstovsek S; Cortes J
Cancer; 2006 Oct; 107(7):1525-9. PubMed ID: 16955510
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Gerrits CJ; Creemers GJ; Schellens JH; Wissel P; Planting AS; Kunka R; Selinger K; de Boer-Dennert M; Marijnen Y; Harteveld M; Verweij J
Br J Cancer; 1996 Mar; 73(6):744-50. PubMed ID: 8611374
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer.
Miller KD; Soule SE; Haney LG; Guiney P; Murry DJ; Lenaz L; Sun SL; Sledge GW
Invest New Drugs; 2004 Jan; 22(1):69-73. PubMed ID: 14707496
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
van Warmerdam LJ; ten Bokkel Huinink WW; Rodenhuis S; Koier I; Davies BE; Rosing H; Maes RA; Beijnen JH
J Clin Oncol; 1995 Jul; 13(7):1768-76. PubMed ID: 7602366
[TBL] [Abstract][Full Text] [Related]
26. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
de Jonge MJ; Punt CJ; Gelderblom AH; Loos WJ; van Beurden V; Planting AS; van der Burg ME; van Maanen LW; Dallaire BK; Verweij J; Wagener DJ; Sparreboom A
J Clin Oncol; 1999 Jul; 17(7):2219-26. PubMed ID: 10561279
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Royce ME; Hoff PM; Dumas P; Lassere Y; Lee JJ; Coyle J; Ducharme MP; De Jager R; Pazdur R
J Clin Oncol; 2001 Mar; 19(5):1493-500. PubMed ID: 11230496
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
31. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Mani S; Iyer L; Janisch L; Wang X; Fleming GF; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42(1):84-7. PubMed ID: 9619763
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
36. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Patel SR; Beach J; Papadopoulos N; Burgess MA; Trent J; Jenkins J; Benjamin RS
Cancer; 2003 Jun; 97(11):2848-52. PubMed ID: 12767099
[TBL] [Abstract][Full Text] [Related]
37. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
38. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
[TBL] [Abstract][Full Text] [Related]
39. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
